Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 Study
Hieken TJ et al. JAMA Surgery.
Validation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study GalleryValidation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study
Validation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study
Weitemeyer et al., Journal of Surgical Oncology.
- Identification of patients at high risk for relapse by Merlin assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: An H&N subgroup analysis. Gallery
Identification of patients at high risk for relapse by Merlin assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: An H&N subgroup analysis.
- Assessing risk of nodal metastasis and relapse-free survival by CP-GEP (Merlin™ Test) in a single-center retrospective case series of stage pT1a-4b cN0M0 melanoma patients Gallery
Assessing risk of nodal metastasis and relapse-free survival by CP-GEP (Merlin™ Test) in a single-center retrospective case series of stage pT1a-4b cN0M0 melanoma patients
Assessing risk of nodal metastasis and relapse-free survival by CP-GEP (Merlin™ Test) in a single-center retrospective case series of stage pT1a-4b cN0M0 melanoma patients
Kessels et al., 2025. World Congress of Melanoma.
- Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients (pts) with stage I/II melanoma who did not undergo sentinel lymph node biopsy Gallery
Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients (pts) with stage I/II melanoma who did not undergo sentinel lymph node biopsy
- Clinicopathologic and gene expression profile (CP-GEP) is a biomarker for outcome in patients with melanoma eligible for sentinel lymph node biopsy (SLNB) Gallery
Clinicopathologic and gene expression profile (CP-GEP) is a biomarker for outcome in patients with melanoma eligible for sentinel lymph node biopsy (SLNB)
Clinicopathologic and gene expression profile (CP-GEP) is a biomarker for outcome in patients with melanoma eligible for sentinel lymph node biopsy (SLNB)
Zijlker et al., 2025. World Congress of Melanoma.
Using CP-GEP model (Merlin Assay) to stratify melanoma patients on long-term survival in a multi-continent cohort study
Utikal et al., 2025. World Congress of Melanoma.
CP-GEP Identifies T1a Melanoma Patients At Risk of Sentinel Lymph Node Metastasis
W. Yu et al. 2024. SMR Conference.
- Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: a H&N subgroup analysis. Gallery
Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: a H&N subgroup analysis.
- Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 432 patients with stage I/II melanoma who did not undergo sentinel lymph node biopsy Gallery
Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 432 patients with stage I/II melanoma who did not undergo sentinel lymph node biopsy
Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 432 patients with stage I/II melanoma who did not undergo sentinel lymph node biopsy
Amaral et al., American Society of Clinical Oncology